The Butterfly: A Novel Minimally Invasive Transurethral Retraction Device for Benign Hypertrophy of the Prostate

Urol Int. 2023;107(4):406-412. doi: 10.1159/000528415. Epub 2023 Jan 31.

Abstract

Introduction: The Butterfly Prostatic Retraction device is a novel transurethral implant designed to dilate the prostatic urethra and treat lower urinary tract symptoms. We assessed its safety, efficacy and impact on urinary flow, ejaculation, and quality of life.

Materials and methods: We included 64 men, treated for benign prostate hyperplasia for at least 1 year. All patients had Qmax≤ 13 mL/s and IPSS >12. Insertion of the device was performed via cystoscopy. Follow-up visits were performed at 2 weeks, 1, 3, 6, and 12 months and included uroflowmetry, IPSS, QoL, and sexual function questionnaires. Cystoscopy was performed on 3 and 12 months.

Results: Patients age was 50-83 years. 28 patients completed a 1-year follow-up with an intact device. Mean Qmax improved by 2 mL/s (25%), IPSS median drop was 10 points (40%), and QoL score was 1.5 points (38%). Sexually active patients reported antegrade ejaculation. On cystoscopy, gradual coverage of the devices with urethral mucosa was observed. In 1 patient, the device was repositioned. In 19 patients, the device was removed. 12 patients returned to alpha-blocker therapy and 7 patients underwent TURP. One patient developed a bulbar urethral stricture.

Conclusions: We demonstrated feasibility and good tolerability of the Butterfly device.

Keywords: Benign prostatic hyperplasia; Bladder outlet obstruction; Lower urinary tract symptoms; Minimally invasive surgical therapy; Urethral devices.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Humans
  • Hypertrophy / surgery
  • Lower Urinary Tract Symptoms* / surgery
  • Male
  • Middle Aged
  • Prostate
  • Prostatic Hyperplasia* / surgery
  • Quality of Life
  • Transurethral Resection of Prostate*
  • Treatment Outcome

Grants and funding

This study was fully funded by Butterfly Medical Ltd. Yoqneam, Israel. The coverage included all hospitalization costs as well as the device itself. Patients or their medical insurance did not pay anything in this study. The company and it's representatives did not take any part in preparing this manuscript.